167 related articles for article (PubMed ID: 28747680)
1. Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.
Pegg CL; Cooper LT; Zhao J; Gerometta M; Smith FM; Yeh M; Bartlett PF; Gorman JJ; Boyd AW
Sci Rep; 2017 Jul; 7(1):6519. PubMed ID: 28747680
[TBL] [Abstract][Full Text] [Related]
2. Insights into Eph receptor tyrosine kinase activation from crystal structures of the EphA4 ectodomain and its complex with ephrin-A5.
Xu K; Tzvetkova-Robev D; Xu Y; Goldgur Y; Chan YP; Himanen JP; Nikolov DB
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14634-9. PubMed ID: 23959867
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity.
Qin H; Noberini R; Huan X; Shi J; Pasquale EB; Song J
J Biol Chem; 2010 Jan; 285(1):644-54. PubMed ID: 19875447
[TBL] [Abstract][Full Text] [Related]
4. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
5. EphA4 provides repulsive signals to developing cochlear ganglion neurites mediated through ephrin-B2 and -B3.
Brors D; Bodmer D; Pak K; Aletsee C; Schäfers M; Dazert S; Ryan AF
J Comp Neurol; 2003 Jul; 462(1):90-100. PubMed ID: 12761826
[TBL] [Abstract][Full Text] [Related]
6. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.
Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB
Biochem J; 2012 Jul; 445(1):47-56. PubMed ID: 22489865
[TBL] [Abstract][Full Text] [Related]
7. EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice.
Goldshmit Y; Spanevello MD; Tajouri S; Li L; Rogers F; Pearse M; Galea M; Bartlett PF; Boyd AW; Turnley AM
PLoS One; 2011; 6(9):e24636. PubMed ID: 21931787
[TBL] [Abstract][Full Text] [Related]
8. EPHA4-FC TREATMENT REDUCES ISCHEMIA/REPERFUSION-INDUCED INTESTINAL INJURY BY INHIBITING VASCULAR PERMEABILITY.
Woodruff TM; Wu MC; Morgan M; Bain NT; Jeanes A; Lipman J; Ting MJ; Boyd AW; Taylor SM; Coulthard MG
Shock; 2016 Feb; 45(2):184-91. PubMed ID: 26771935
[TBL] [Abstract][Full Text] [Related]
9. Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.
Guo FY; Lesk AM
Proteins; 2014 Mar; 82(3):349-53. PubMed ID: 24105818
[TBL] [Abstract][Full Text] [Related]
10. Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling.
Bowden TA; Aricescu AR; Nettleship JE; Siebold C; Rahman-Huq N; Owens RJ; Stuart DI; Jones EY
Structure; 2009 Oct; 17(10):1386-97. PubMed ID: 19836338
[TBL] [Abstract][Full Text] [Related]
11. Regulation of axonal EphA4 forward signaling is involved in the effect of EphA3 on chicken retinal ganglion cell axon growth during retinotectal mapping.
Fiore L; Medori M; Spelzini G; Carreño CO; Carri NG; Sanchez V; Scicolone G
Exp Eye Res; 2019 Jan; 178():46-60. PubMed ID: 30237102
[TBL] [Abstract][Full Text] [Related]
12. Lipidation and PEGylation Strategies to Prolong the
Gomez-Soler M; Olson EJ; de la Torre ER; Zhao C; Lamberto I; Flood DT; Danho W; Lechtenberg BC; Riedl SJ; Dawson PE; Pasquale EB
Eur J Med Chem; 2023 Dec; 262():. PubMed ID: 38523699
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
14. Identification of the Jak/Stat proteins as novel downstream targets of EphA4 signaling in muscle: implications in the regulation of acetylcholinesterase expression.
Lai KO; Chen Y; Po HM; Lok KC; Gong K; Ip NY
J Biol Chem; 2004 Apr; 279(14):13383-92. PubMed ID: 14729671
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols.
Noberini R; Koolpe M; Lamberto I; Pasquale EB
Pharmacol Res; 2012 Oct; 66(4):363-73. PubMed ID: 22750215
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations.
Singla N; Goldgur Y; Xu K; Paavilainen S; Nikolov DB; Himanen JP
Biochem Biophys Res Commun; 2010 Sep; 399(4):555-9. PubMed ID: 20678482
[TBL] [Abstract][Full Text] [Related]
17. Eph receptor tyrosine kinases regulate astrocyte cytoskeletal rearrangement and focal adhesion formation.
Puschmann TB; Turnley AM
J Neurochem; 2010 May; 113(4):881-94. PubMed ID: 20202079
[TBL] [Abstract][Full Text] [Related]
18. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Saintigny P; Peng S; Zhang L; Sen B; Wistuba II; Lippman SM; Girard L; Minna JD; Heymach JV; Johnson FM
Mol Cancer Ther; 2012 Sep; 11(9):2021-32. PubMed ID: 22807579
[TBL] [Abstract][Full Text] [Related]
19. Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model.
Bhatia S; Hirsch K; Baig NA; Rodriguez O; Timofeeva O; Kavanagh K; Lee YC; Wang XJ; Albanese C; Karam SD
J Hematol Oncol; 2015 Sep; 8():105. PubMed ID: 26345456
[TBL] [Abstract][Full Text] [Related]
20. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
